GLP-1 CV & Kidney Meta-Analysis

Source: The Lancet Diabetes & Endocrinology (2021).

Key finding: Consistent CV and renal benefit across GLP-1 RAs.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
WHO Guideline on Pharmacological Treatment of Obesity
Semaglutide in Adults with Prediabetes and Obesity or Overweight (STEP 10)
Oral Semaglutide 25 mg Once Daily for Obesity (OASIS 4)

Take the Free Eligibility Assessment → · Compare All 18+ Brands